Charlotte Parker, Author at Oral Cancer News

Many Head and Neck Cancer Survivors Face Eating Problems

Source: HealthDay News Persistent pain, eating problems and depression are the most common problems experienced by long-term survivors of head and neck cancer, a new study finds. In the study, published in the Jan. 16 online issue of the journal Archives of Otolaryngology -- Head & Neck Surgery, researchers looked at 337 people who were diagnosed with head and neck cancer from 1995 to 2004 and survived at least five years. More than 50 percent of the survivors had problems eating because of poor throat functioning, 28.5 percent had symptoms of depression and more than 17 percent had substantial pain, the researchers found. However, when the long-term survivors were compared to age-matched people in the general population, their average general health was similar, Dr. Gerry Funk, of the University of Iowa Hospitals and Clinics in Iowa City, and colleagues explained in a journal news release. The investigators also found that pain and diet in the first year after cancer treatment were the strongest independent predictors of five-year, health-related quality-of-life outcomes. Problems with mouth and throat function in head and neck cancer survivors can be due to factors such as neuromuscular changes, anatomic deficits after surgery, pain and dental problems, the researchers noted. "Early interventions addressing eating issues, swallowing problems and pain management will be a crucial component in improving this patient population's long-term quality of life, especially in those who are functioning poorly one year after diagnosis," the study authors concluded. This story was also covered in a narrative form [...]

Charlotte Parker2012-01-18T13:54:28-07:00January, 2012|Oral Cancer News|

Fluorescent spray that can catch throat cancer early offers hope to 8,000 Britons diagnosed each year

Source: Dailymail.co.uk A throat spray has been developed to spot cancer of the oesophagus at an early stage. The disease, which killed Morse star John Thaw, is one of the most deadly cancers because it is often missed or wrongly diagnosed until too late. Current methods used to detect it can be inaccurate, so many patients are given unnecessary invasive treatment including removal of their oesophagus, the ‘food pipe’ that connects the throat to the stomach. Early detection key: If caught early, the cancerous cells can be zapped with an electric current which kills them without surgery. Now scientists have developed a fluorescent dye spray which sticks to healthy cells in the oesophagus but cannot attach itself to cancer cells or those in the early stages of turning cancerous. This gives a clear signpost to where the disease is developing. If caught at this stage, the cancer cells can be ‘zapped’ with an electric current which kills them without surgery. The treatment offers hope to more than 8,000 Britons a year who are diagnosed with oesophageal cancer. One of the patients in the study had their entire oesophagus removed because a small pre-cancerous area had been identified – which using the dye was found to have been very small and could have been treated without surgery. Deadly: Oesophageal cancer is one of the most fatal because it is often missed or wrongly diagnosed until it is too late. Two patients whose cancer had not shown up using the current imaging [...]

Charlotte Parker2012-01-17T10:22:33-07:00January, 2012|Oral Cancer News|

New Indicator May Help Identify Patients With Increased Risk From Throat Cancer

Source: Marketwatch.com ANN ARBOR, Mich., Jan. 16, 2012 /PRNewswire via COMTEX/ -- Independent of other factors, such as smoking history and HPV status, matted lymph nodes appear to signal increased chance of oropharyngeal cancer spreading to other parts of the body. Researchers at the University of Michigan Health System have found a new indicator that may predict which patients with a common type of throat cancer are most likely have the cancer spread to other parts of their bodies. Patients with oropharyngeal squamous cell carcinoma who had "matted" lymph nodes - nodes that are connected together - had a 69 percent survival rate over three years, compared to 94 percent for patients without matted nodes, according to a study published online ahead of print publication in Head & Neck. The oropharynx is an area that includes the back of the tongue, soft palate, throat and tonsils. "The spread of cancer throughout the body accounts for about 45 percent of the deaths from oropharyngeal carcinoma," says the study's senior author, Douglas B. Chepeha, M.D., M.S.P.H., an associate professor of otolaryngology head and neck surgery at the U-M Medical School. "Our findings may help doctors identify patients who are at higher risk for having their cancer metastasize and who would benefit from additional systemic therapy. Conversely, some patients without matted nodes may benefit from a reduction of the current standard treatment, which would cut down on uncomfortable side effects." Notably, the findings indicate an increased risk independent of other established prognostic factors, [...]

Charlotte Parker2012-01-16T10:04:24-07:00January, 2012|Oral Cancer News|

Lab-made tissue picks up the slack of Petri dishes in cancer research

New research demonstrates that previous models used to examine cancer may not be complex enough to accurately mimic the true cancer environment. Using oral cancer cells in a three-dimensional model of lab-made tissue that mimics the lining of the oral cavity, the researchers found that the tissue surrounding cancer cells can epigenetically mediate, or temporarily trigger, the expression or suppression of a cell adhesion protein associated with the progression of cancer. These new findings support the notion that drugs that are currently being tested to treat many cancers need to be screened using more complex tissue-like systems, rather than by using conventional petri dish cultures that do not fully manifest features of many cancers. "Research on cancer progression has been drawn largely using models that grow cancer cells in plastic dishes. Our research reveals a major shortcoming in the experimental systems used to study cancer development. When using simplified culture systems in which cells are grown on plastic, cancer cells grow as a two dimensional monolayer and lack the three-dimensional tissue structure seen in human cancer. As a result, complex interactions that occur between the cancer cells and the surrounding tissue layers are not accounted for," said first author Teresa DesRochers, PhD, a graduate of the Sackler School of Graduate Biomedical Sciences at Tufts, currently in the department of biomedical engineering at Tufts University School of Engineering. The researchers report that the three-dimensional network of cell interactions activates epigenetic mechanisms that control whether genes critical for cancer development will be [...]

Charlotte Parker2012-01-11T15:02:12-07:00January, 2012|Oral Cancer News|

Which Cancers Are Increasing Among Older Adults?

Source: AARP Cancers of the mouth and throat related to oral sex, as well as thyroid, liver and skin cancers are on the rise among older adults, according to new stats released last week from the American Cancer Society. There was some good news, however. The death rate is down for the well-known major cancers. The society’s Cancer Statistics 2012 report found that overall, cancer deaths dropped by nearly two percent for both men and women from 2004 to 2008. That may sound paltry, but Len Lichtenfeld, M.D., the society’s deputy chief medical officer, says it is more significant than it seems: Many people avoided even hearing the words “you have cancer” because advances in cancer treatment caught problems early, while still in the pre-cancerous stage, he said. The report found that death rates were down for all four major cancers — lung, colorectal, breast and prostate. The biggest drop was for lung cancer, which is down almost 40 percent in the number of men dying from the disease, thanks to fewer Americans smoking. Deaths among women from breast cancer declined 34 percent, mainly because of increases in mammogram screening and a decrease in hormone use for menopause, the ACS report said. On the other hand, some cancers are increasing, particularly among older Americans. According to Medscape News , the ACS found that people 55 to 64 years of age had the highest increase in incidence rates for liver and HPV-related oral cancers; people 65 and older also had an increase in incidence rates [...]

Charlotte Parker2012-01-10T14:48:32-07:00January, 2012|Oral Cancer News|

Lymphedema is highly common in oral cancer treatment

Source: Elsevier Global Medical News SAN FRANCISCO (EGMN) – Lymphedema is highly common and a source of considerable morbidity among patients who undergo treatment for head and neck cancer, finds a cross-sectional study among 103 survivors. Fully three-fourths had developed some degree of lymphedema, according to results presented at the annual Oncology Congress presented by Reed Medical Education. The more severe it was, the more likely patients were to have symptoms, functional impairments, and poorer quality of life. Disease and treatment-related factors such as high radiation dose and combined surgery and radiation therapy were risk factors for the development of lymphedema. “This is the first study that we are aware of in the United States of this depth to systematically examine lymphedema” in this population, noted lead investigator Jie Deng, Ph.D., R.N., O.C.N., a postdoctoral fellow at the Vanderbilt University, Nashville, Tenn. “Health care professionals should be aware that lymphedema is a frequent late effect in the head and neck cancer population,” she advised. “We need to educate patients about the risk of lymphedema prior to treatment, during treatment, and posttreatment, and we need to conduct external and internal examinations to evaluate related signs and symptoms at each clinic visit.” Patients found to have any signs or symptoms should be referred for lymphedema assessment. Furthermore, “it’s very important we have very detailed documentation so we can follow up on patients’ treatment effect and also identify potential issues in this population,” Dr. Deng stressed. “An interdisciplinary approach is needed to [...]

Charlotte Parker2012-01-08T20:18:17-07:00January, 2012|Oral Cancer News|

Oral Cancer Foundation Sponsors 13th Annual Oral Cancer Awareness Month in April 2012

Source: Dentistry IQ Organization encouraging dental professionals to offer free screenings to the public Did you know that the fastest growing segment of the oral cancer community is young, healthy non-smokers? It's shocking but true. Exposure to the HPV-16 virus, the most common sexually transmitted infection, is now the leading cause of oral cancers in the U.S. There is little that can be done to stop this virus from spreading. Our only hope to save lives is through increased professional involvement and public awareness to generate early discovery of the disease process. To that end, the Oral Cancer Foundation (OCF) is encouraging the dental community to get involved in Oral Cancer Awareness Month this April 2012 by offering free oral cancer screenings to the public in a national effort to raise awareness of this silent killer. Oral cancer has existed outside the consciousness of much of the public, which is one reason 37,000 Americans will be newly diagnosed this year alone. That is about 100 new people a day. That lack of awareness has contributed to this cancer not being discovered until very late in its development. By implementing a public awareness campaign, OCF wants to educate the public about the risk factors, early signs and symptoms of the disease, as well as the need for all adults to undergo an annual oral cancer screening. In the early stages of oral cancer's development, it is often is painless, and physical signs may not be obvious to an individual. This makes [...]

Charlotte Parker2012-01-07T16:54:51-07:00January, 2012|OCF In The News, Oral Cancer News|

Anti-cancer vaccines are emerging

Source: Boston Globe Author: Karen Weintraub Long envisioned drugs to harness the immune system could reshape treatments For more than a century, doctors and patients have dreamed of using the body’s own defenses to fight cancer. Why, they wondered, can’t the immune system - so good at tracking down and destroying intruders - attack the tumor cells that invade healthy tissue? Finally, science is catching up with this vision. Just reaching the market in a big way, so-called therapeutic vaccines turn a patient’s immune system against the cancer and help prevent a recurrence. If the early promise of these vaccines is realized, they will soon join the basic arsenal for fighting all cancers, several researchers said. “We really are in a transformative moment,’’ said Dr. Glenn Dranoff, professor of medicine at Harvard Medical School and a medical oncologist and immunologist at the Dana-Farber Cancer Institute. Prostate cancer patients were the first to benefit. A therapeutic vaccine called Provenge received federal approval last year after studies showed it safely extended the lives of advanced prostate cancer patients for an average of 4.1 months. Then came a vaccine called Yervoy, designed to attack melanoma, a particularly dangerous form of skin cancer. Cancer generally turns down the body’s immune response to a tumor; Yervoy is designed to turn it back on, enhancing the immune system’s ability to kill cancer cells. Many more cancer vaccines are under development, with hundreds of trials underway in patients with breast, prostate, lung, kidney, colon, cervical, brain, and [...]

Charlotte Parker2011-12-19T14:52:52-07:00December, 2011|Oral Cancer News|

Study Finds- Fewer Dying from Throat & Mouth Cancer in the U.S.

Source: HealthDay News, US News and World Report Author: Staff Death rates improved most for patients with more than 12 years' education Death rates for U.S. patients with throat and mouth cancers decreased between 1993 and 2007, a new study shows. The finding comes from an analysis of National Center for Health Statistics data on white and black men and women, aged 25 to 64, in 26 states. The researchers also found that the largest decreases in death rates for mouth and throat (pharynx) cancers were among black patients with at least 12 years of education. The study appears in the November issue of the Archives of Otolaryngology -- Head & Neck Surgery. Death rates increased among white men with fewer than 12 years of education, according to Dr. Amy Y. Chen, of Emory University School of Medicine and the American Cancer Society, and colleagues. Another study in the same issue of the journal found that poor overall quality of life, pain and continued tobacco use seem to be associated with poorer outcomes and a higher death rate two years after diagnosis for patients with head and neck cancer. The study included 276 patients diagnosed between September 2001 and September 2008. The overall survival rate two years after diagnosis was 90.8 percent. The likelihood of death within two years of diagnosis was: four times higher for those who reported low quality of life than for those who reported a high quality of life; four times higher for those who continued [...]

Charlotte Parker2011-11-22T09:05:47-07:00November, 2011|Oral Cancer News|

Data Published in the Lancet Oncology Support High Efficacy Previously Demonstrated By Cervarix

Source: Therapeutics Daily Author: Staff LONDON, Nov. 9, 2011-An analysis published today in The Lancet Oncology reinforces previous findings showing that GlaxoSmithKline’s Cervarix®, provided protection against advanced precancerous lesions (CIN3+), above that expected from a vaccine that protects against human papillomavirus (HPV) types 16 and 18. CIN3+ is the immediate step before invasive cervical cancer and data showing protection against this type of lesion are considered the most stringent evidence of potential cervical cancer prevention.1 Results from the largest efficacy trial of a cervical cancer vaccine to date (PATRICIA), show that Cervarix provided 93%† efficacy against CIN3+ irrespective of the HPV type associated with the CIN3+ lesion.1This pre-defined, exploratory analysis was conducted in women with no evidence of past or current HPV infection.‡ These women are thought to be representative of young girls prior to the onset of sexual activity – the primary target population for organised vaccination programmes. These findings have been incorporated into the European label for Cervarix, updated by the European Commission in September 2011. Additional data from the same end-of-study analysis have been published in a separate article in TheLancet Oncology. These data demonstrate that Cervarix provided 82%* efficacy against CIN3+, associated with a composite of 12 cancer-causing HPV types not included in the vaccine, in the same population as the analysis discussed above.2 This analysis excluded cases co-infected with HPV 16 and/or 18 and is therefore a conservative estimate of cross-protective efficacy. Non-vaccine HPV types, including the 12 studied in this analysis, together account for approximately 30% of cervical cancers globally.3 The authors [...]

Charlotte Parker2011-11-16T12:04:02-07:00November, 2011|Oral Cancer News|

Oral Cancer News
Compiled by The Oral Cancer Foundation

About Charlotte Parker